By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shire Pharmaceuticals Group plc 

Hampshire International Business Park
Basingstoke  Hampshire  RG24 8EP  United Kingdom
Phone: 44-1256-894-000 Fax: 44-1256-894-708


Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its first two years of operation, the company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter, innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer's disease and end-stage renal failure.

By 1992, Shire had embarked on the first of what would be a series of strategic acquisitions -- these were bold ventures that fortified our product lines and underscored the wisdom of a business model focused exclusively on products sold to specialist physicians. After the turn of the millennium, with the acquisition of TKT, we began our focus on rare diseases, something that remains a strategic focus for the company today. The Shire pipeline continues to be sustained by creative acquisitions and innovative licensing deals. Smart commercialization strategies have ensured that the right patients and the right physicians have the information they need to make appropriate choices about treatment options.

In June 2016, Shire completed a combination with Baxalta, creating the world’s leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. With over 22,000 employees across more than 100 countries, Shire’s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs.




FOUNDER: Harry Stratford

CEO: Flemming Ornskov

CFO: Jeffrey Poulton


Please click here for Shire job opportunities..


Please click here for clinical trial information..


Please click here for product information..


Key Statistics

Ownership: Public

Web Site: Shire
Symbol: SHPG


Company News
Shire (SHPG) To Announce Second Quarter 2017 Results 7/18/2017 10:56:32 AM
Shire (SHPG) Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement For NovImmune SA Bi-Specific Antibody 7/18/2017 10:54:14 AM
Shire (SHPG) Hits Roche (RHHBY) With An Injunction Over Hemophilia Drug 7/10/2017 5:41:45 AM
Shire (SHPG) Submits Investigational New Drug Application To FDA For Gene Therapy Candidate SHP654 For Treatment Of Hemophilia A 7/6/2017 11:23:53 AM
Shire (SHPG) to Consolidate 3,000+ Jobs Over 4 Years to 2 Massachusetts Sites 6/30/2017 6:28:09 AM
Shire (SHPG) Announces EMA Validation Of Veyvondi [Von Willebrand Factor (Recombinant)] Marketing Authorization Application For Treatment Of Von Willebrand Disease 6/22/2017 10:02:57 AM
Shire (SHPG): U.S. FDA Approves Mydayis (Mixed Salts Of A Single-Entity Amphetamine Product) - A New Once-Daily Option For ADHD Symptom Control In Patients 13 Years And Older 6/21/2017 10:20:02 AM
Biogen (BIIB) Brings Ex-Shire (SHPG) Exec Into C-Suite 6/20/2017 5:57:34 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Kamada Ltd. (KMDA) Receives Additional Milestone Payment Under GLASSIA Exclusive Supply And Distribution Agreement With Shire (SHPG) 6/12/2017 12:01:24 PM